Citations (66)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Ze Wang, Li Zhao, Bo Zhang, Jiahe Feng, Yule Wang, Bin Zhang, Haixiao Jin, Lijian Ding, Ning Wang & Shan He. (2023) Discovery of novel polysubstituted N-alkyl acridone analogues as histone deacetylase isoform-selective inhibitors for cancer therapy. Journal of Enzyme Inhibition and Medicinal Chemistry 38:1.
Read now
Read now
Varun Dewaker, Pratik Narain Srivastava, Saroj Verma, Ajay K. Srivastava & Yenamandra S. Prabhakar. (2022) Non-bonding energy directed designing of HDAC2 inhibitors through molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics 40:24, pages 13432-13455.
Read now
Read now
Yi-Xin Lv, Sheng Tian, Zhou-Dong Zhang, Tao Feng & Huan-Qiu Li. (2022) LSD1 inhibitors for anticancer therapy: a patent review (2017-present). Expert Opinion on Therapeutic Patents 32:9, pages 1027-1042.
Read now
Read now
Varun Dewaker, Ajay K. Srivastava, Ashish Arora & Yenamandra S. Prabhakar. (2021) Investigation of HDAC8-ligands’ intermolecular forces through molecular dynamics simulations: profiling of non-bonding energies to design potential compounds as new anti-cancer agents. Journal of Biomolecular Structure and Dynamics 39:13, pages 4726-4751.
Read now
Read now
Guoyi Yan, Dongxiao Li, Xinxin Zhong, Ge Liu, Xueqin Wang, Yuanxiang Lu, Fangyuan Qin, Yuqi Guo, Shaofeng Duan & Deyu Li. (2021) Identification of HDAC6 selective inhibitors: pharmacophore based virtual screening, molecular docking and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics 39:6, pages 1928-1939.
Read now
Read now
Mauro Alaibac. (2018) Small molecule inhibitors for cutaneous T-cell lymphomas. Expert Opinion on Orphan Drugs 6:5, pages 345-350.
Read now
Read now
Articles from other publishers (60)
Juanbin Yin, Shasha Wang, Shanhui Ren, Zhengji Liang, Junwei Ge, Yuefeng Sun, Xiangping Yin & Xiangwei Wang. (2023) TMP269, a small molecule inhibitor of class IIa HDAC, suppresses RABV replication in vitro. Frontiers in Microbiology 14.
Crossref
Crossref
Chen Gong, Jiazhuo Wu, Wenting Song, Hongwen Li, Cunzhen Shi, Yuyang Gao, Zhuangzhuang Shi, Zhaoming Li & Mingzhi Zhang. (2023) Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer/T-cell lymphoma. Annals of Hematology.
Crossref
Crossref
Daqiang Li, Zhuo Zhang, Yalei Li, Xinyi Wang, Hanyue Zhong, Huajie Yang, Yong Xi, Hongchun Liu, Aijun Shen & Youhong Hu. (2023)
Discovery of (
S
)-
N
-(2-Amino-4-fluorophenyl)-4-(1-(3-(4-((dimethylamino)methyl)phenyl)-6-oxopyridazin-1(6
H
)-yl)ethyl)benzamide as Potent Class I Selective HDAC Inhibitor for Oral Anticancer Drug Candidate
. Journal of Medicinal Chemistry 66:10, pages 7016-7037.
Crossref
Crossref
Yangdan Liu, Dongsheng Wen, Chiakang Ho, Li Yu, Danning Zheng, Steven O’Reilly, Ya Gao, Qingfeng Li & Yifan Zhang. (2023) Epigenetics as a versatile regulator of fibrosis. Journal of Translational Medicine 21:1.
Crossref
Crossref
Urvashi Patel, Joshua P. Smalley & James T. Hodgkinson. (2023) PROTAC chemical probes for histone deacetylase enzymes. RSC Chemical Biology.
Crossref
Crossref
LinLiang ZHANG, Qi DONG & MingZhou CHEN. (2022) The roles of protein acetylation in viral life cycle. SCIENTIA SINICA Vitae 52:9, pages 1369-1376.
Crossref
Crossref
Margarita E. Neganova, Sergey G. Klochkov, Yulia R. Aleksandrova & Gjumrakch Aliev. (2022) Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress. Seminars in Cancer Biology 83, pages 452-471.
Crossref
Crossref
Ramanjulu Abinaya, Santhanam Srinath, S. Soundarya, Radhakrishnan Sridhar, Kalpattu Kuppusamy Balasubramanian & Baburaj Baskar. (2022) Recent Developments on Synthesis Strategies, SAR Studies and Biological Activities of β-Carboline Derivatives – An Update. Journal of Molecular Structure 1261, pages 132750.
Crossref
Crossref
Narissara Namwan, Gulsiri Senawong, Chanokbhorn Phaosiri, Pakit Kumboonma, La-or Somsakeesit, Arunta Samankul, Chadaporn Leerat & Thanaset Senawong. (2022) HDAC Inhibitory and Anti-Cancer Activities of Curcumin and Curcumin Derivative CU17 against Human Lung Cancer A549 Cells. Molecules 27:13, pages 4014.
Crossref
Crossref
Yingying Zhao, Hongwen Xuan, Chao Shen, Peiyi Liu, Jing-Dong J. Han & Wei Yu. (2022) Immunosuppression Induced by Brain-Specific HDAC6 Knockdown Improves Aging Performance in Drosophila melanogaster. Phenomics 2:3, pages 194-200.
Crossref
Crossref
Eftiola Pojani & Daniela Barlocco. (2022) Selective Inhibitors of Histone Deacetylase 10 (HDAC-10). Current Medicinal Chemistry 29:13, pages 2306-2321.
Crossref
Crossref
Dongsheng Wen, Ya Gao, Chiakang Ho, Li Yu, Yuguang Zhang, Guozhong Lyu, Dahai Hu, Qingfeng Li & Yifan Zhang. (2022) Focusing on Mechanoregulation Axis in Fibrosis: Sensing, Transduction and Effecting. Frontiers in Molecular Biosciences 9.
Crossref
Crossref
Davide Bonanni, Andrea Citarella, Davide Moi, Luca Pinzi, Elisa Bergamini & Giulio Rastelli. (2022) Dual Targeting Strategies on Histone Deacetylase 6 (HDAC6) and Heat Shock Protein 90 (Hsp90). Current Medicinal Chemistry 29:9, pages 1474-1502.
Crossref
Crossref
Tae Hoon Kim, Steven L Young, Tsutomu Sasaki, Jeffrey L Deaton, David P Schammel, Wilder Alberto Palomino, Jae-Wook Jeong & Bruce A Lessey. (2022) Role of SIRT1 and Progesterone Resistance in Normal and Abnormal Endometrium. The Journal of Clinical Endocrinology & Metabolism 107:3, pages 788-800.
Crossref
Crossref
Chenxia Ding, Benyu Su, Qiaoling Li, Wenwen Ding, Guochao Liu, Zuchao Cai, Fengmei Zhang, David Lim & Zhihui Feng. (2022) Histone deacetylase inhibitor 2-hexyl-4-pentynoic acid enhances hydroxyurea therapeutic effect in triple-negative breast cancer cells. Mutation Research/Genetic Toxicology and Environmental Mutagenesis 873, pages 503422.
Crossref
Crossref
Anupam Mittal, Rajni Garg, Ajay Bahl & Madhu Khullar. (2021) Molecular Mechanisms and Epigenetic Regulation in Diabetic Cardiomyopathy. Frontiers in Cardiovascular Medicine 8.
Crossref
Crossref
Disha Agarwal, Ruchika Kumari, Ashal Ilyas, Shweta Tyagi, Rajnish Kumar & Nitesh Kumar Poddar. (2021) Crosstalk between epigenetics and mTOR as a gateway to new insights in pathophysiology and treatment of Alzheimer's disease. International Journal of Biological Macromolecules 192, pages 895-903.
Crossref
Crossref
Fangyuan Cao, Zhangping Xiao, Siwei Chen, Chunlong Zhao, Deng Chen, Hidde J. Haisma & Frank J. Dekker. (2021) HDAC/MIF dual inhibitor inhibits NSCLC cell survival and proliferation by blocking the AKT pathway. Bioorganic Chemistry 117, pages 105396.
Crossref
Crossref
Xiangyu Ke, Zhirui Lin, Zebing Ye, Meifang Leng, Bo Chen, Chunjie Jiang, Xiaoyun Jiang & Guowei Li. (2021) Histone Deacetylases in the Pathogenesis of Diabetic Cardiomyopathy. Frontiers in Endocrinology 12.
Crossref
Crossref
Giuseppe Campiani, Caterina Cavella, Jeremy D. Osko, Margherita Brindisi, Nicola Relitti, Simone Brogi, A. Prasanth Saraswati, Stefano Federico, Giulia Chemi, Samuele Maramai, Gabriele Carullo, Benedikt Jaeger, Alfonso Carleo, Rosaria Benedetti, Federica Sarno, Stefania Lamponi, Paola Rottoli, Elena Bargagli, Carlo Bertucci, Daniele Tedesco, Daniel Herp, Johanna Senger, Giovina Ruberti, Fulvio Saccoccia, Simona Saponara, Beatrice Gorelli, Massimo Valoti, Breándan Kennedy, Husvinee Sundaramurthi, Stefania Butini, Manfred Jung, Katy M. RoachLucia Altucci, Peter BraddingDavid W. Christianson, Sandra Gemma & Antje Prasse. (2021) Harnessing the Role of HDAC6 in Idiopathic Pulmonary Fibrosis: Design, Synthesis, Structural Analysis, and Biological Evaluation of Potent Inhibitors. Journal of Medicinal Chemistry 64:14, pages 9960-9988.
Crossref
Crossref
Lei Zhong, Yueshan Li, Liang Xiong, Wenjing Wang, Ming Wu, Ting Yuan, Wei Yang, Chenyu Tian, Zhuang Miao, Tianqi Wang & Shengyong Yang. (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Øystein Bruserud, Galina Tsykunova, Maria Hernandez-Valladares, Hakon Reikvam & Tor Henrik Anderson Tvedt. (2021) Therapeutic Use of Valproic Acid and All-Trans Retinoic Acid in Acute Myeloid Leukemia—Literature Review and Discussion of Possible Use in Relapse after Allogeneic Stem Cell Transplantation. Pharmaceuticals 14:5, pages 423.
Crossref
Crossref
I. V. Vystorop, G. V. Shilov, A. V. Chernyak, E. N. Klimanova, T. E. Sashenkova, S. G. Klochkov, M. E. Neganova, Yu. R. Aleksandrova, U. Yu. Allayarova & D. V. Mishchenko. (2021) Regioselective Synthesis, Structure, and Chemosensitizing Antitumor Activity of Cyclic Hydroxamic Acid Based on DL-Valine. Russian Journal of Bioorganic Chemistry 47:3, pages 757-764.
Crossref
Crossref
Kuojun Zhang, Zhiyi Liu, Yiwu Yao, Yatao Qiu, Feng Li, Dong Chen, Dale J. Hamilton, Zheng Li & Sheng Jiang. (2021) Structure-Based Design of a Selective Class I Histone Deacetylase (HDAC) Near-Infrared (NIR) Probe for Epigenetic Regulation Detection in Triple-Negative Breast Cancer (TNBC). Journal of Medicinal Chemistry 64:7, pages 4020-4033.
Crossref
Crossref
Sarah F. Giardina, Elena Valdambrini, J. David Warren & Francis Barany. (2021) PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug Resistance. Current Cancer Drug Targets 21:4, pages 306-325.
Crossref
Crossref
Feng Song, Yunqiang Bian, Jing Liu, Zhenghua Li, Li Zhao, Junman Fang, Yonghong Lai & Meng Zhou. (2021) Indole Alkaloids, Synthetic Dimers and Hybrids with Potential In Vivo Anticancer Activity. Current Topics in Medicinal Chemistry 21:5, pages 377-403.
Crossref
Crossref
Yu Bao, Qihao Xu, Lin Wang, Yunfei Wei, Baichun Hu, Jian Wang, Dan Liu, Linxiang Zhao & Yongkui Jing. (2021) Studying Histone Deacetylase Inhibition and Apoptosis Induction of Psammaplin A Monomers with Modified Thiol Group. ACS Medicinal Chemistry Letters 12:1, pages 39-47.
Crossref
Crossref
Kyoung-Tae Kim, Young-Seok Lee & Inbo Han. (2020) The Role of Epigenomics in Osteoporosis and Osteoporotic Vertebral Fracture. International Journal of Molecular Sciences 21:24, pages 9455.
Crossref
Crossref
Jianfu Zhang, Jianzhao Peng, Yiran Huang, Ling Meng, Qingrong Li, Feng Xiong & Xiaoyu Li. (2020) Identification of Histone deacetylase (HDAC)‐Associated Proteins with DNA‐Programmed Affinity Labeling. Angewandte Chemie International Edition 59:40, pages 17525-17532.
Crossref
Crossref
Jianfu Zhang, Jianzhao Peng, Yiran Huang, Ling Meng, Qingrong Li, Feng Xiong & Xiaoyu Li. (2020) Identification of Histone deacetylase (HDAC)‐Associated Proteins with DNA‐Programmed Affinity Labeling. Angewandte Chemie 132:40, pages 17678-17685.
Crossref
Crossref
Tingting Liu, Zhongyu Wu, Yujing He, Yuliang Xiao & Chengcai Xia. (2020) Single and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy. European Journal of Medicinal Chemistry 201, pages 112446.
Crossref
Crossref
Mona Dawood, Mohamed Elbadawi, Madeleine Böckers, Gerhard Bringmann & Thomas Efferth. (2020) Molecular docking-based virtual drug screening revealing an oxofluorenyl benzamide and a bromonaphthalene sulfonamido hydroxybenzoic acid as HDAC6 inhibitors with cytotoxicity against leukemia cells. Biomedicine & Pharmacotherapy 129, pages 110454.
Crossref
Crossref
Neha Upadhyay, Kalpana Tilekar, Niklas Jänsch, Markus Schweipert, Jessica D. Hess, Luca Henze Macias, Piotr Mrowka, Renato J. Aguilera, Jun-yong Choe, Franz-Josef Meyer-Almes & C.S. Ramaa. (2020) Discovery of novel N-substituted thiazolidinediones (TZDs) as HDAC8 inhibitors: in-silico studies, synthesis, and biological evaluation. Bioorganic Chemistry 100, pages 103934.
Crossref
Crossref
Bingbing Zhang, Zhu-Wei Ruan, Dongdong Luo, Yueyue Zhu, Tingbo Ding, Qiang Sui & Xinsheng Lei. (2020) Unexpected Enhancement of HDACs Inhibition by MeS Substitution at C-2 Position of Fluoro Largazole. Marine Drugs 18:7, pages 344.
Crossref
Crossref
Balázs Zoltán Zsidó & Csaba Hetényi. (2020) Molecular Structure, Binding Affinity, and Biological Activity in the Epigenome. International Journal of Molecular Sciences 21:11, pages 4134.
Crossref
Crossref
Xingrui He, Zhen Li, Xiao-Tao Zhuo, Zi Hui, Tian Xie & Xiang-Yang Ye. (2020) Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019). Recent Patents on Anti-Cancer Drug Discovery 15:1, pages 32-48.
Crossref
Crossref
Kuojun Zhang, Yiwu Yao, Zhengchao Tu, Chenzhong Liao, Zhen Wang, Yatao Qiu, Dong Chen, Dale J Hamilton, Zheng Li & Sheng Jiang. (2020) Discovery of class I histone deacetylase inhibitors based on romidpesin with promising selectivity for cancer cells. Future Medicinal Chemistry 12:4, pages 311-323.
Crossref
Crossref
Faria Sultana, Kesari Lakshmi Manasa, Siddiq Pasha Shaik, Srinivasa Reddy Bonam & Ahmed Kamal. (2020) Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Current Medicinal Chemistry 26:40, pages 7212-7280.
Crossref
Crossref
Kalpana Tilekar, Neha Upadhyay, Niklas Jänsch, Markus Schweipert, Piotr Mrowka, F.J. Meyer-Almes & C.S. Ramaa. (2020) Discovery of 5-naphthylidene-2,4-thiazolidinedione derivatives as selective HDAC8 inhibitors and evaluation of their cytotoxic effects in leukemic cell lines. Bioorganic Chemistry 95, pages 103522.
Crossref
Crossref
Barbara Vergani, Giovanni Sandrone, Mattia Marchini, Chiara Ripamonti, Edoardo Cellupica, Elisabetta Galbiati, Gianluca Caprini, Gianfranco Pavich, Giulia Porro, Ilaria Rocchio, Maria Lattanzio, Marcello Pezzuto, Malgorzata Skorupska, Paola Cordella, Paolo Pagani, Pietro Pozzi, Roberta Pomarico, Daniela Modena, Flavio Leoni, Raffaella Perego, Gianluca Fossati, Christian Steinkühler & Andrea Stevenazzi. (2019) Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation. Journal of Medicinal Chemistry 62:23, pages 10711-10739.
Crossref
Crossref
Francesco Massari, Vincenzo Di Nunno, Veronica Mollica, Rodolfo Montironi, Liang Cheng, Alessia Cimadamore, Ana Blanca & Antonio Lopez-Beltran. (2019) Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy 11:17, pages 1507-1521.
Crossref
Crossref
Anton V. Kolotaev, Karine R. Matevosyan, Vasiliy N. Osipov & Derenik S. Khachatryan. (2019) Synthesis of new quinazoline-containing hydroxamic acids as potential HDAC/VEGFR inhibitors. Unusual rearrangements with pyrrolidone ring opening and dehydration of 3-N-hydroxyquinazoline fragment containing tetracycles. Tetrahedron Letters 60:51, pages 151315.
Crossref
Crossref
Bingbing Zhang, Jiami Liu, Dingding Gao, Xiaolin Yu, Jinlei Wang & Xinsheng Lei. (2019) A fluorine scan on the Zn2+-binding thiolate side chain of HDAC inhibitor largazole: Synthesis, biological evaluation, and molecular modeling. European Journal of Medicinal Chemistry 182, pages 111672.
Crossref
Crossref
Lei Zhong, Shu Zhou, Rongsheng Tong, Jianyou Shi, Lan Bai, Yuxuan Zhu, Xingmei Duan, Wenzhao Liu, Jinku Bao, Lingyu Su & Qian Peng. (2018) Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinoma. Investigational New Drugs 37:4, pages 616-624.
Crossref
Crossref
Yanqing Liu, Omid Tavana & Wei Gu. (2019) p53 modifications: exquisite decorations of the powerful guardian. Journal of Molecular Cell Biology 11:7, pages 564-577.
Crossref
Crossref
Yong Ling, Yangyang Li, Rui Zhu, Jianqiang Qian, Ji Liu, Weijie Gao, Chi Meng, Jiefei Miao, Biao Xiong, Xiaodong Qiu, Changchun Ling, Hong Dai & Yanan Zhang. (2019) Hydroxamic Acid Derivatives of β-Carboline/Hydroxycinnamic Acid Hybrids Inducing Apoptosis and Autophagy through the PI3K/Akt/mTOR Pathways. Journal of Natural Products 82:6, pages 1442-1450.
Crossref
Crossref
Veronica Mollica, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Alessia Cimadamore, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi, Salvatore Pisconti, Nicola Battelli & Francesco Massari. (2019) Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution. Clinical Drug Investigation 39:6, pages 503-519.
Crossref
Crossref
Yong Ling, Wei-Jie Gao, Changchun Ling, Ji Liu, Chi Meng, Jianqiang Qian, Siqun Liu, Huiling Gan, Hongmei Wu, Jinhua Tao, Hong Dai & Yanan Zhang. (2019) β-Carboline and N-hydroxycinnamamide hybrids as anticancer agents for drug-resistant hepatocellular carcinoma. European Journal of Medicinal Chemistry 168, pages 515-526.
Crossref
Crossref
Danielle Q Calcagno, Fernanda Wisnieski, Elizangela R da Silva Mota, Stefanie B Maia de Sousa, Jéssica M Costa da Silva, Mariana F Leal, Carolina O Gigek, Leonardo C Santos, Lucas T Rasmussen, Paulo P Assumpção, Rommel R Burbano & Marília AC Smith. (2019) Role of histone acetylation in gastric cancer: implications of dietetic compounds and clinical perspectives. Epigenomics 11:3, pages 349-362.
Crossref
Crossref
Xing Lyu, Min Hu, Jieting Peng, Xiangyu Zhang & Yan Y Sanders. (2019) HDAC inhibitors as antifibrotic drugs in cardiac and pulmonary fibrosis. Therapeutic Advances in Chronic Disease 10, pages 204062231986269.
Crossref
Crossref
Linglong Yin, Youhong Liu, Yuchong Peng, Yongbo Peng, Xiaohui Yu, Yingxue Gao, Bowen Yuan, Qianling Zhu, Tuoyu Cao, Leye He, Zhicheng Gong, Lunquan Sun, Xuegong Fan & Xiong Li. (2018) PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells. Journal of Experimental & Clinical Cancer Research 37:1.
Crossref
Crossref
Edwin Choy, Karla Ballman, James Chen, Mark A. Dickson, Rashmi Chugh, Suzanne George, Scott Okuno, Raphael Pollock, Rajiv M. Patel, Antje Hoering & Shreyaskumar Patel. (2018) SARC018_SPORE02: Phase II Study of Mocetinostat Administered with Gemcitabine for Patients with Metastatic Leiomyosarcoma with Progression or Relapse following Prior Treatment with Gemcitabine-Containing Therapy. Sarcoma 2018, pages 1-9.
Crossref
Crossref
Yao Wang, Lei Zhao, Fang-Zhou Jiao, Wen-Bin Zhang, Qian Chen & Zuo-Jiong Gong. (2018) Histone deacetylase inhibitor suberoylanilide hydroxamic acid alleviates liver fibrosis by suppressing the transforming growth factor-β1 signal pathway. Hepatobiliary & Pancreatic Diseases International 17:5, pages 423-429.
Crossref
Crossref
Oluwaseun Adebayo Bamodu, Kuang-Tai Kuo, Li-Ping Yuan, Wei-Hong Cheng, Wei-Hwa Lee, Yuan-Soon Ho, Tsu-Yi Chao & Chi-Tai Yeh. (2018) HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of hsa-miR-196a targeting BCR/ABL1. Experimental Cell Research 370:2, pages 519-530.
Crossref
Crossref
Tiantian Qin, Weihua Liu, Junfeng Huo, Leilei Li, Xueyan Zhang, Xiaoli Shi, Jinlei Zhou & Cong Wang. (2018) SIRT1 expression regulates the transformation of resistant esophageal cancer cells via the epithelial-mesenchymal transition. Biomedicine & Pharmacotherapy 103, pages 308-316.
Crossref
Crossref
Jalal Choupani, Sima Mansoori Derakhshan, Sahar Bayat, Mohammad Reza Alivand & Mahmoud Shekari Khaniani. (2018) Narrower insight to SIRT1 role in cancer: A potential therapeutic target to control epithelial-mesenchymal transition in cancer cells. Journal of Cellular Physiology 233:6, pages 4443-4457.
Crossref
Crossref
Fangyuan Cao, Martijn Zwinderman & Frank Dekker. (2018) The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors. Molecules 23:3, pages 551.
Crossref
Crossref
Sugandha Bhatia, James Monkman, Alan Kie Leong Toh, Shivashankar H. Nagaraj & Erik W. Thompson. (2017) Targeting epithelial–mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring. Biochemical Journal 474:19, pages 3269-3306.
Crossref
Crossref
Thomas Efferth. (2017) Cancer combination therapies with artemisinin-type drugs. Biochemical Pharmacology 139, pages 56-70.
Crossref
Crossref
Lin-Lin Cao, Xiaoxu Song, Lin Pei, Lianhua Liu, Hui Wang & Mei Jia. (2017) Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer. Medicine 96:31, pages e7663.
Crossref
Crossref